1. Home
  2. LMB vs COLL Comparison

LMB vs COLL Comparison

Compare LMB & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Limbach Holdings Inc.

LMB

Limbach Holdings Inc.

HOLD

Current Price

$80.69

Market Cap

1.1B

ML Signal

HOLD

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

HOLD

Current Price

$32.42

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LMB
COLL
Founded
1901
2002
Country
United States
United States
Employees
1400
N/A
Industry
Engineering & Construction
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
LMB
COLL
Price
$80.69
$32.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$116.67
$51.17
AVG Volume (30 Days)
181.9K
547.7K
Earning Date
03-02-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
25.68
N/A
EPS
3.23
1.73
Revenue
$646,804,000.00
$780,567,000.00
Revenue This Year
$15.96
$5.93
Revenue Next Year
$5.90
N/A
P/E Ratio
$24.90
$19.32
Revenue Growth
24.68
23.62
52 Week Low
$63.02
$23.23
52 Week High
$154.04
$50.79

Technical Indicators

Market Signals
Indicator
LMB
COLL
Relative Strength Index (RSI) 47.61 24.32
Support Level $77.96 $31.01
Resistance Level $85.30 $32.92
Average True Range (ATR) 4.28 1.30
MACD 0.37 -0.04
Stochastic Oscillator 65.93 1.07

Price Performance

Historical Comparison
LMB
COLL

About LMB Limbach Holdings Inc.

Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

Share on Social Networks: